What it is: Artificial Intelligence Expert SRL (AIE) provides an end-to-end biomedical data analysis service that turns complex multi-omics and clinical datasets into validated, explainable biomarker panels and patient-level predictive models — the full pipeline from raw heterogeneous data to an interpretable, regulatory-ready AI model.

Duration: Typically 6–16 weeks, depending on data scale and the number of modalities.

Targets and sectors: EIC Pathfinder and Transition beneficiaries and Seal of Excellence holders in health, biotechnology, diagnostics, and pharmaceuticals that generate genomic, epigenomic, proteomic, metabolomic, microbiome, or clinical data.

Goal: To give early-stage health innovators regulatory-ready biomarker evidence and explainable models, removing the specialised data-science barrier to clinical validation and investor due diligence.

Phases and activities: 

• (1) multi-site data harmonisation and quality control using validated bioinformatics pipelines; 
• (2) dimensionality reduction from up to millions of raw features to compact panels; 
• (3) AutoML benchmarking across 12–15 algorithms; 
• (4) SHAP explainability at feature, modality, and patient level; 
• (5) functional pathway interpretation; 
• (6) documentation aligned with the EU AI Act and FDA SaMD transparency requirements.
   

Expected outcome: A validated biomarker panel and explainable predictive model, delivered with reproducible pipelines and regulatory-ready documentation.

Implementation: Delivered remotely by AIE's in-house data-science team under secure, GDPR-compliant data exchange;results provided as interactive reports with a live review session. Track record: OPADE (350 patients, 13 modalities, AUC 0.81) and i-Biomarker CaDx (99–100% accuracy, 32 cancer types).